MarketCap
Facebook
X
Telegram
UroGen Pharma Ltd. Income Statement 2025-2011 | URGN
Brief overview of profit and loss at UroGen Pharma Ltd.
The overview follows changes across a five-year period. The revenue attributed to UroGen Pharma Ltd. moved from 11.8 million dollars to 110 million dollars between the two endpoints. The cumulative result was +830.5%, corresponding to roughly 56.2% per year. Sales grew at a rate typical of a strong expansion phase.
At the gross-profit level, the result moved from $10.8 million to $97.3 million, a change of +802.1%. Direct costs outpaced revenue, limiting the benefit of changes in sales. At the margin level, the figure shifted from 91.4% to 88.7%. The contraction points to pressure from direct costs or weaker pricing power.
EBITDA was −125 million dollars at the beginning and −125 million dollars at the end of the period (+0.1%). EBITDA underperformed the top-line trend. EBITDA margin was −1056.8% at the start and −113.5% at the end. A wider margin confirms stronger operating efficiency.
Net income moved from −$128 million at the start to −$153 million at the end. Larger losses indicate rising pressure on the business.
Market value was 487 million dollars at the start and 924 million dollars at the end. The share-price trend moved ahead of the financial performance.
Overall conclusion
The indicators point to a weaker financial profile. Key strengths include sales growth and an improving EBITDA margin. The most visible risks are limited operating profitability, declining net profitability and pressure from direct costs. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement UroGen Pharma Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
924 M | 823 M | 518 M | 193 M | 173 M | 487 M | 617 M | 654 M | 484 M | - | - | - | - | - | - |
Shares |
48.1 M | 42.9 M | 36.2 M | 22.8 M | 22.3 M | 22.1 M | 20.5 M | 15.8 M | 9.72 M | - | - | - | - | - | - |
Historical Prices |
19.2 | 19.2 | 14.3 | 8.48 | 7.72 | 22.1 | 29.4 | 41.4 | 49.1 | - | - | - | - | - | - |
Net Income |
-153 M | -127 M | -102 M | -110 M | -111 M | -128 M | -105 M | -75.7 M | -20 M | -1.94 M | -12.7 M | - | - | - | - |
Revenue |
110 M | 90.4 M | 23.5 M | 64.4 M | 48 M | 11.8 M | 18 K | 1.13 M | 8.16 M | 17.5 M | - | - | - | - | - |
Cost of Revenue |
12.4 M | 8.88 M | 9.36 M | 7.65 M | 5.16 M | 1.01 M | - | 1.8 M | 600 K | 28 K | - | - | - | - | - |
Gross Profit |
97.3 M | 81.5 M | 21.2 M | 56.7 M | 42.9 M | 10.8 M | 18 K | -675 K | 7.56 M | 17.5 M | - | - | - | - | - |
Operating Income |
-125 M | -96.8 M | -65.5 M | -79 M | -92.3 M | -127 M | -109 M | -77.2 M | -20 M | 798 K | -12.4 M | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | -284 K | -124 K | 12 K | - | - | - | - | - | - |
EBITDA |
-125 M | -96.5 M | -64.7 M | -78.1 M | -91.5 M | -125 M | -108 M | -76.8 M | -19.7 M | 1.01 M | -12.3 M | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 138 M | 109 M | 76.5 M | 27.5 M | 16.7 M | - | - | - | - | - |
General and Administrative Expenses |
155 M | 121 M | 93.3 M | 82.8 M | 87.5 M | 90.2 M | 60.2 M | 39.6 M | 8.81 M | 6.42 M | 1.9 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement UroGen Pharma Ltd.
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
50.4 M | 50.2 M | 48.1 M | 47.7 M | 47.4 M | 42.2 M | 46.8 M | 40.5 M | 33.4 M | 32.5 M | 32.3 M | 23.5 M | 23.3 M | 23.1 M | 22.8 M | 22.7 M | 22.6 M | 22.5 M | 22.4 M | 22.3 M | 22.2 M | 22.2 M | 22.1 M | 21.8 M | 21.2 M | 21 M | 20.9 M | 20.8 M | 19.3 M | 16.2 M | 16.1 M | 15.8 M | 15.3 M | 13.8 M | 13.1 M | 9.2 M | 2.31 M | 2.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-14.4 M | -23.6 M | -33.3 M | -49.9 M | -43.8 M | - | -23.7 M | -33.4 M | -32.3 M | - | -21.9 M | -24.1 M | -30.2 M | - | -25.8 M | -26.7 M | -28.4 M | - | -30.2 M | -26.2 M | -25.9 M | - | -28.8 M | -31.3 M | -37.8 M | -39 M | -22.3 M | -22.5 M | -21.4 M | -23.7 M | -20.5 M | -18 M | -13.4 M | -10.1 M | -298 K | -6.2 M | -3.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
72.5 M | 51 M | 27.5 M | 24.2 M | 20.3 M | - | 25.2 M | 21.8 M | 18.8 M | - | 20.9 M | 21.1 M | 17.2 M | - | 16.1 M | 16.6 M | 13.6 M | - | 11.4 M | 13 M | 7.48 M | - | 3.46 M | 372 K | - | - | 18 K | 18 K | - | - | 283 K | 364 K | 481 K | 327 K | 7.81 M | - | 19 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
6.57 M | 4.14 M | 3.28 M | 3.55 M | 2.33 M | - | 2.45 M | 2.23 M | 1.73 M | - | 2.37 M | 2.44 M | 2.26 M | - | 2.02 M | 1.85 M | 1.52 M | - | 1.24 M | 1.43 M | 897 K | - | 309 K | 48 K | - | - | - | - | - | - | 1.06 M | 318 K | 430 K | - | 295 K | - | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
65.9 M | 46.8 M | 24.2 M | 20.7 M | 17.9 M | - | 22.8 M | 19.6 M | 17.1 M | - | 18.5 M | 18.7 M | 14.9 M | - | 14.1 M | 14.8 M | 12 M | - | 10.1 M | 11.6 M | 6.59 M | - | 3.15 M | 324 K | - | - | 18 K | 18 K | - | - | -772 K | 46 K | 51 K | - | 7.52 M | - | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
111 K | -20.3 M | -27.4 M | -41.4 M | -36.9 M | - | -17.5 M | -25.8 M | -25.7 M | - | -13.5 M | -15.4 M | -22 M | - | -18.1 M | -18.7 M | -22 M | - | -23.4 M | -22.8 M | -26.1 M | - | -29.1 M | -31.8 M | -38.6 M | -39.8 M | -23.5 M | -23.8 M | -22.4 M | -24 M | -21.1 M | -18.4 M | -13.6 M | -10.2 M | -303 K | -5.95 M | -3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.39 M | 911 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
211 K | -20.2 M | -27.3 M | -41.3 M | -36.8 M | - | -17.4 M | -25.7 M | -25.6 M | - | -13.3 M | -15.2 M | -21.8 M | - | -17.9 M | -18.5 M | -21.7 M | - | -23.2 M | -22.6 M | -25.9 M | - | -29 M | -31.7 M | -38.5 M | -39.8 M | -23.4 M | -23.7 M | -22.3 M | -24 M | -21 M | -18.4 M | -13.4 M | -10.2 M | -303 K | -5.95 M | -3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.8 M | 23.5 M | 23.8 M | 22.4 M | 24 M | 20.3 M | 18.5 M | 13.7 M | 10.2 M | 7.82 M | 5.95 M | 3.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
48.4 M | 51.5 M | 37.6 M | 43.2 M | 35 M | - | 28.9 M | 30.1 M | 27.3 M | - | 21.8 M | 22.5 M | 24.5 M | - | 19.1 M | 20.8 M | 21.3 M | - | 21.6 M | 22.3 M | 22.2 M | - | 22.1 M | 24 M | 22 M | - | 14 M | 13.8 M | 12.7 M | - | 10.7 M | 10.2 M | 6.07 M | - | 2.2 M | 2.3 M | 875 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company UroGen Pharma Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada